/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/
The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business days, through SEDAR+
SASKATOON, SK, July 7, 2026 /CNW/ - PHARMACORP RX INC. ("PharmaCorp" or the "Company") (TSXV: PCRX) is pleased to announce that it has entered into an agreement with a syndicate of underwriters (the "Underwriters") co-led by Acumen Capital Finance Partners Limited ("Acumen") and Canaccord Genuity Corp. pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, 19,608,000 units (the "Units") in the capital of the Company at a price of C$0.51 per Unit (the "Offering Price") for aggregate gross proceeds to the Company of C$10,000,080 (the "Offering").
Each Unit shall consist of one common share (a "Common Share") in the capital of the Company and one-half (1/2) of one Common Share purchase warrant (each whole warrant, a "Warrant") of the Company. Each whole Warrant shall entitle the holder thereof to acquire one Common Share at an exercise price per Common Share of C$0.60 for a period of 24 months from the Closing Date (as defined below).
The net proceeds of the Offering shall be used to fund future acquisition opportunities and general working capital requirements.
The closing of the Offering is expected to occur on or about July 14, 2026 (the "Closing Date") and is subject to the completion of formal documentation and receipt of all regulatory approvals, including the approval of the TSX Venture Exchange.
The Company has granted the Underwriters an option (the "Over-Allotment Option"), exercisable, in whole or in part, by Acumen, on behalf of the Underwriters, giving notice to the Company at any time and from time to time up to 30 days following the Closing Date, to purchase, or to find substituted purchasers for, up to an additional number of Units equal to 15% of the number of Units sold pursuant to the Offering at the Offering Price to cover over-allotments, if any, and for market stabilization purposes.
The Units to be issued under the Offering will be offered by way of a prospectus supplement (the "Prospectus Supplement") to the Company's final short form base shelf prospectus dated October 14, 2025 (the "Base Shelf Prospectus") which will be filed with the securities commissions or securities regulatory authorities in each of the provinces of Canada, except Quebec. Delivery of the Base Shelf Prospectus and the Prospectus Supplement and any amendments thereto will be satisfied in accordance with the "access equals delivery" provisions of applicable Canadian securities legislation. Copies of the Prospectus Supplement, following filing thereof, and the Base Shelf Prospectus may be obtained on SEDAR+ at www.sedarplus.ca and from Acumen Capital Finance Partners Limited at info@acumencapital.com. The Prospectus Supplement and the Base Shelf Prospectus contain important detailed information about the Company and the proposed Offering. Prospective investors should read the Prospectus Supplement, the Base Shelf Prospectus, and the other documents the Company has filed on SEDAR+ at www.sedarplus.ca before making an investment decision.